ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
+65 6436 8000
- Provision of a voluntarily given, personally signed and dated, written informed consent document;
- Age ≥20 years in Japan and Korea, and ≥18 years in other countries, male or female;
- The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen determined by the local laboratory;
- Evidence of newly diagnosed stage IIIB/IV (based on Union for International Cancer Control (UICC) staging system version 8) or recurrent (minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC required) NSCLC of adenocarcinoma histo- and/or cytopathology or its pathologically accepted variants using tumor specimen (assessed according to accepted standards by a local laboratory). For this purpose the World Health Organization/International Association of Study of Lung Cancer Histologic Classification of Lung Cancer Criteria will be used and the diagnosis of NSCLC NOS (not otherwise specified), squamous or mixed adeno-squamous lung carcinomas will not be allowed;
- Have an ECOG PS of 0 or 1;
- No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;
- Radiologically measurable disease by RECIST v1.1 criteria:
1. At least one target lesion that has not previously been radiated, and is measurable according to RECIST v1.1;
2. Acceptable radiologic procedures for disease assessment include contrast enhanced conventional or spiral computed tomography (CT), or contrast enhanced magnetic resonance imaging (MRI); Non-contrast CT scan is acceptable only for subjects who are both allergic to intravenous contrast and unable to cooperate with MRI, or MRI is not available. The following are not allowed as sole documentation of target lesions: CT component of positron emission tomography (PET)/CT, ultrasound alone, nuclear scans (including bone or PET scans), chest X-ray or bone radiographs, and tumor markers;
- Adequate organ function, including:
1. Estimated creatinine clearance ≥30 mL/min (as determined by Cockcroft-Gault formula or the study site's standard formula);
2. Absolute neutrophil count (ANC) ≥1500 cells/mm3;
3. Platelets ≥100,000 cells/mm3;
4. Hemoglobin ≥10.0 g/dL;
5. Bilirubin ≤1.5 x ULN;
6. AST (also known as SGOT) and ALT (also known as SGPT) ≤2.5 x ULN (≤5.0 x ULN if hepatic metastases).
- Female subjects must be postmenopausal (defined as 12 months of amenorrhea following last menses), or they or their partners must be surgically sterile, or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator using following criteria:
a. Acceptable contraception for women include implants, injectables, combined oral contraceptives, intrauterine devices (IUDs), sexual abstinence, or a partner who has been surgically sterile (e.g. by vasectomy) for at least 6 months. Acceptable contraception for a male includes surgical sterility (e.g. by vasectomy) for at least 6 months, sexual abstinence, or condoms plus spermicide.
- All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to starting study treatment;
- Male subjects or their female partners must be surgically sterile or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator. Or female partners must be postmenopausal (defined as 12 months of amenorrhea following last menses);
- Willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures.
- Any evidence of mixed histo- and/or cytology that includes elements of small cell or
carcinoid lung cancer. Variations of adenocarcinoma are allowed, however no squamous
element can be present;
- An EGFR exon 20 T790M or exon 20 insertion mutation;
- Symptomatic brain or leptomeningeal metastases, who are neurologically unstable or
require increasing doses of steroids and/or anti-seizure medications to manage CNS
symptoms within two weeks prior to starting dacomitinib;
- Any previous anti-cancer systemic treatment of locally advanced, or metastatic NSCLC
including but not limited to chemotherapy, targeted therapies, small molecules,
EGFR-TKIs and other TKIs, monoclonal antibodies, anti-cancer vaccines, immunotherapy,
radiotherapy (other than palliative radiotherapy to lesions that will not be followed
for tumor assessment on this study, i.e., non-target lesions). Completed
neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/
radiation therapy permitted only in cases in which there is a minimum of 12 months
disease free interval between completion of systemic therapy and recurrence of NSCLC.
Prior treatment with a EGFR-TKI or other TKIs is not allowed;
- Any surgery (not including minor procedures such as lymph node biopsy), palliative
radiotherapy or pleurodesis within 2 weeks of baseline assessments;
- Any clinically significant gastrointestinal abnormalities that may impair intake,
transit or absorption of the study drug, such as the inability to take oral
medication;
- Current enrollment in another therapeutic clinical study;
- Any psychiatric or cognitive disorder that would limit the understanding or rendering
of informed consent and/or compromise compliance with the requirements of this study;
or known drug abuse/alcohol abuse;
- History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial
lung disease including:
1. Past medical history of interstitial lung disease, drug-induced interstitial
disease, radiation pneumonitis which required steroid treatment or any evidence
of clinically active interstitial lung disease;
2. Pre-existing idiopathic pulmonary fibrosis evidenced by CT scan at baseline;
3. Insufficient lung function as determined by either clinical examination or an
arterial oxygen tension of <70 Torr.
- Any history of rare hereditary problems of galactose intolerance, total lactase
deficiency or glucose-galactose malabsorption
- Clinically important abnormalities in cardiac rhythm, conduction or morphology of
resting ECG (e.g. complete left bundle branch block, second degree heart block, third
degree heart block) OR:
1. Diagnosed or suspected congenital long QT syndrome;
2. Any history of clinically significant ventricular arrhythmias (such as
ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);
3. Prolonged QTc interval on ECG; QTc must be less than CTCAE v5.0 Grade 2 (≤480
msec) using Fridericia's or Bazett's correction formula with a manual reading by
the investigator if required. The ECG may be repeated for evaluation of
eligibility after management of correctable causes for observed QTc prolongation;
4. Any history of second or third degree heart block;
5. Heart rate <45 beats per minute on ECG in the presence of clinical symptoms
(e.g., hypotension, evidence of hypoperfusion);
- Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction;
- Prior malignancy: Subjects will not be eligible if they have history of, or evidence
of active disease of another concurrent malignancy within the previous five years.
Exception would be effectively treated past history of non-melanoma skin cancer or
in-situ cervical cancer with no evidence of active disease;
- Other severe acute or chronic medical condition that may increase the risk associated
with study participation or study drug administration or may interfere with the
interpretation of study results and, in the judgment of the investigator, would make
the subject inappropriate for entry into this study;
- Use of CYP2D6 substrates where minimal increases in concentration of the CYP2D6
substrate may lead to serious or life-threatening toxicities, including but not
limited to procainamide, pimozide, and thioridazine from screening to randomization.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Hong Kong,
- Hong Kong,
- Petaling Jaya,
- Busan,
- Seoul,
- Kuching, Sarawak
- Kuala Lumpur,
- Singapore,
- Bangkok,
- Bangkok,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | Phase 2 Study of Dacomitinib in NSCLC | ||||||
Official Title ICMJE | A Single-arm, Open-label, Phase 2 Study of Dacomitinib With or Without Dose Titration for the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Subjects With an Epidermal Growth Factor Receptor (EGFR) Activation Mutation | ||||||
Brief Summary | This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage IIIB/IV or recurrent EGFR-mutation-positive non-small cell lung cancer (NSCLC). National Cancer Centre Singapore will be the lead sponsor acting in a coordinating capacity and the rest of the participating sites are sponsors of their own individual sites. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||||
Condition ICMJE |
| ||||||
Intervention ICMJE | Drug: Dacomitinib
30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg. Other Name: Vizimpro | ||||||
Study Arms ICMJE | Experimental: Treatment
Daily administration of oral Dacomitinib Intervention: Drug: Dacomitinib | ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE | 118 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Estimated Study Completion Date ICMJE | June 28, 2024 | ||||||
Estimated Primary Completion Date | June 30, 2022 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
| ||||||
Listed Location Countries ICMJE | Hong Kong, Korea, Republic of, Malaysia, Singapore, Thailand | ||||||
Removed Location Countries | Taiwan | ||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT04027647 | ||||||
Other Study ID Numbers ICMJE | ATORG-003 | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | National Cancer Centre, Singapore | ||||||
Study Sponsor ICMJE | National Cancer Centre, Singapore | ||||||
Collaborators ICMJE | Pfizer | ||||||
Investigators ICMJE |
| ||||||
PRS Account | National Cancer Centre, Singapore | ||||||
Verification Date | September 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |